

Immunohistochemical Expression of p16 and CDK4 in Soft Tissue Tumors

Pankaj Deval¹, Kaveri Agrawal², Mala Sagar³

¹Assistant Professor, Department of Pathology, Venkateshwar Institute of Medical Sciences, Gajraula, Amroha, ²Senior Resident, Department of Pathology, Rama Medical College and Hospital, Hapur, ³Professor, Department of Pathology, KGMU Lucknow.

How to cite this article: Pankaj Deval, Kaveri Agrawal, Mala Sagar. Immunohistochemical Expression of p16 and CDK4 in Soft Tissue Tumors. Indian Journal of Public Health Research & Development 2023;14(3).

Abstract

Background: The large majority of soft tissue tumours are benign. Malignant mesenchymal neoplasms amount to less than 1% of the overall human burden of malignant tumours but they are life threatening and may pose a significant diagnostic and therapeutic challenge since there are more than 50 histological subtypes of STS, which are often associated with unique clinical, prognostic and therapeutic features.

Methods: The study was undertaken in department of Pathology, King George's Medical University, Lucknow. The Study Design was Retrospective and prospective study carried over a period of one year from September 2018 to August 2019 including 70 cases.

Results: Most common diagnosis of malignant cases was Synovial sarcoma (21.4%) followed by Leiomyosarcoma (19.0%) and Undifferentiated pleomorphic sarcoma & Fibromyxoid sarcoma (11.9% each). Less common diagnosis were Ewing's sarcoma, Liposarcoma and Rhabdomyosarcoma (9.5% each), 1 (2.4%) case each was diagnosed as Chondrosarcoma, MPNST and Myxoid liposarcoma.

Conclusions: Genetic alterations involving the 12q13-15 chromosomal region are common in musculoskeletal sarcomas, and many bone and soft-tissue malignant tumors showed amplification of various genes located in this region.

Keywords: synovial sarcoma; ewing's sarcoma; histopathological

Introduction

The large majority of soft tissue tumours are benign. Malignant mesenchymal neoplasms amount to less than 1% of the overall human burden of malignant tumours but they are life threatening and may pose a significant diagnostic and therapeutic challenge since there are more than 50 histological subtypes of STS, which are often associated with unique clinical, prognostic and therapeutic features.¹

The aetiology of most benign and malignant soft tissue tumours is unknown. In rare cases, genetic and environmental factors, irradiation, viral infections and immune deficiency have been found associated with the development of usually malignant soft tissue tumours.² However, the large majority of soft tissue sarcomas seem to arise de novo, without an apparent causative factor. In this study we analyse the expression of CDK4 and p16 in the various

Corresponding Author: Kaveri Agarwal, Senior Resident, Department of Pathology, Rama Medical College and Hospital, Hapur.

E-mail: kaveriagrawal@yahoo.co.in

Mobile: 7565999660

lineages of soft tissue sarcoma and their role in differentiating atypical lipomatoustumor/WDL from benign lipomas.³

Material and Methods

The study was undertaken in department of Pathology, King George's Medical University, Lucknow. The Study Design was Retrospective and prospective study carried over a period of one year from September 2018 to August 2019 including 70 cases with

Inclusion Criteria: Histologically diagnosed cases of soft tissue tumors.

Exclusion Criteria: Inadequate biopsy tissue for immunohistochemistry.

Results

The present study was conducted in the Department of Pathology in collaboration of Departments of Surgical Oncology and Orthopedics, King George's Medical University, Lucknow to study the immunohistochemical expression of p16 and CDK4 markers in various lineages of soft tissue sarcomas. In the present study, 70 histologically diagnosed cases of soft tissue tumors fulfilling the inclusion criteria were enrolled in the study.

Age of patients enrolled in the study ranged from 1 to 97 years, mean age was found to be 34.98 ± 19.96 years. Most common age groups were 31-40 years (20.0%) followed by 11-20 years and 41-50 years (18.6% each).

Out of 70 patients enrolled, majority were males (61.4%) and rest 38.6% were females.

Most common site of swelling were lower extremity (34.3%) followed by head and neck (22.9%) and Upper extremity (11.4%) while less common sites of swelling were Back and Trunk (8.6% each) and Pelvic and Retroperitoneum (7.1% each).

Majority of the patients presented with pain (61.4%) and showed progression of swelling (84.3%).

Duration of symptoms in majority of the patients was >6 months (77.1%).

Minimum size of tumour was 1 cm while maximum size was 18 cms. Mean size of tumour was

7.09 ± 4.52 cms. Only 5 (7.1%) cases had tumour size >15 cm, 12.9% had tumour size 11-15 cm, 34.3% had tumour size 6-10 cm and rest 45.7% had tumour size ≤ 5 cm.

Excisional biopsy was done for majority of the cases (80.0%) and for rest of the cases Incisional biopsy was done (20.0%).

Out of 70 cases enrolled in the study, 42 (60.0%) were histopathologically found to be malignant, 20 (28.6%) as benign and rest 6 (11.4%) as intermediate.

Out of 20 cases histopathologically found to be benign, Lipoma was the most common diagnosis (25.0%) followed by Angiomyolipoma, Benign fibromyxoid neoplasm, Calcifying fibrous tumour and Fibroma (15.0% each), 1 (5.0%) case each was diagnosed as Dermatofibroma, hemangioma and myxoma.

Most common diagnosis of malignant cases was Synovial sarcoma (21.4%) followed by Leiomyosarcoma (19.0%) and Undifferentiated pleomorphic sarcoma & Fibromyxoid sarcoma (11.9% each). Less common diagnosis were Ewing's sarcoma, Liposarcoma and Rhabdomyosarcoma (9.5% each), 1 (2.4%) case each was diagnosed as Chondrosarcoma, MPNST and Myxoid liposarcoma.

Among histopathologically intermediate cases most common diagnosis was DFSP (62.5%) followed by Well differentiated liposarcoma (25.0%) and Low grade myofibroblastic sarcoma (12.5%).

Age of histologically benign cases ranged between 9 to 56 years of age, mean age was 29.55 ± 15.37 years. Difference in age of benign cases with different diagnosis was not found to be significant statistically.

Range of age of histopathologically malignant cases was 1 to 97 years, mean age of these cases was 36.58 ± 22.56 years. Age of 1 case each of Chondrosarcoma, MPNST and Myxoid liposarcoma was 40, 16 and 74 years respectively. Minimum mean age was observed for cases diagnosed as Rhabdomyosarcoma (1.88 ± 0.85 years) followed by Ewing's sarcoma (12.25 ± 6.29 years) while mean age was maximum for cases diagnosed as myxoid liposarcoma (74.00 ± 0.00 yrs) followed by Undifferentiated pleomorphic sarcoma (61.60 ± 25.58 years). Difference in mean age of malignant cases

with different diagnosis was found to be significant statistically.

Age of histopathologically intermediate cases ranged between 23 to 64 years, mean age was 40.13 ± 13.27 years. Minimum mean age was observed for cases diagnosed as low grade myofibroblastic sarcoma (27.00 ± 0.00 yrs) followed by DFSP (36.60 ± 9.76 years) while maximum age was observed for cases diagnosed as Well differentiated liposarcoma (55.50 ± 12.02 years). Difference in age of intermediate cases with different diagnosis was not found to be significant statistically.

Among benign cases majority were males (70.0%) and rest were females. Male preponderance was found for all the above diagnosis except for Dermatofibroma (33.3% males only). Difference in gender of benign cases with different diagnosis was not found to be significant statistically.

Out of 42 malignant cases 23 (54.8%) were male and rest were females. Male preponderance was seen for cases diagnosed as Chondrosarcoma, MPNST (100.0% each), Lipo sarcoma (75.0%) and synovial sarcoma (66.7%). Ewing's sarcoma and Leiomyosarcoma were present in equal proportion of males and females. Female preponderance was seen for cases diagnosed as Myxoid liposarcoma (100.0%), Fibromyxoid sarcoma (80.0%), Rhabdomyosarcoma (75.0%). Difference in gender of malignant cases with different diagnosis was not found to be significant statistically.

Out of 8 histopathologically intermediate cases 6 (75.0%) were males. Male preponderance was observed for cases diagnosed as DFSP (80.0%) and low grade myofibroblastic sarcoma (100.0%) while male:female ratio was similar cases diagnosed as Well differentiated liposarcoma. Difference in gender of histopathologically diagnosed intermediate cases with above diagnosis was not found to be significant statistically.

Positive p16 expression was observed in majority of the cases (51.4%) while negative p16 expression was observed for 44.3% cases and rest were found to be focal positive (4.3%).

Negative CDK4 expression was observed in majority of the cases (81.4%) while positive CDK4

expression was observed for 10.0% cases and rest were found to be focal positive (8.6%).

Both p16 & CDK4 positive expression was observed in only 12.9% cases, 38.3% had both negative expression and rest 48.6% cases had positive expression either for p16 or CDK4.

Negative p16 expression was observed among higher proportion of Benign as compared to malignant and intermediate cases (75.0% vs. 31.0% & 37.5%) while positive p16 expression was observed among higher proportion of malignant as compared to Benign & intermediate cases (66.7% vs. 20.0% & 50.0%) while focal positive expression was observed in higher proportion of Intermediate as compared to Benign & Malignant cases (12.5% vs. 5.0% & 2.4%). This difference was found to be significant statistically.

Negative CDK4 expression was observed among higher proportion of Benign as compared to malignant and intermediate cases (90.0% vs. 78.6% & 75.0%) while positive CDK4 expression was observed among higher proportion of Intermediate as compared to Benign & malignant cases (25.0% vs. 5.0% & 9.5%) while focal positive expression was observed in higher proportion of malignant cases as compared to Benign & Intermediate cases (11.9% vs. 5.0% & 0.0%). This difference was not found to be significant statistically.

Both p16 & CDK4 negative expression was observed among higher proportion of Benign as compared to malignant and intermediate cases (65.0% vs. 26.2% & 37.5%) while among higher proportion of malignant as compared to Benign & intermediate cases had either positive expression (57.1% vs. 35.0% & 37.5%), positive expression was observed among higher proportion of Intermediate as compared to benign and malignant (25.0% vs. 0.0% & 16.7%). This difference was not found to be significant statistically.

Out of 45 diagnosed cases of Sarcoma, majority had FNLCC Grade 3 (62.2%), only 11.1% were Grade 2 and rest 26.7% were Grade 1 cases.

TNM Staging was done for 31 cases. Majority of the cases were pT1 and pT2 (67.7%), only 12.9% cases were pT4 and rest 19.4% were pT3 stage.

An increment in p16 negative expression with increase in FNLCC Grade was observed (8.3%, 20.0% & 39.3%) while p16 positive expression was found to be higher in Grade 1 as compared to Grade 2 and Grade 3 (83.3% vs. 60.0% & 60.7%). Association of p16 expression with FNLCC grade was not found to be significant statistically.

Association of p16 expression with TNM staging was not found to be significant statistically.

A decline in CDK4 negative expression with increase in FNLCC Grade was observed (83.3%, 80.0% & 71.4%) while CDK4 positive expression was found to be higher in Grade 2 as compared to Grade 1 and Grade 3 (20.0% vs. 16.7% & 10.7%). Association of CDK4 expression with FNLCC Grade was not found to be significant statistically.

Association of CDK4 expression with TNM staging was also not found to be significant statistically.

For adipocytic tumors, majority of the benign tumours had negative expression of p16 (6/8; 75%) and CDK4 (8/8; 100%) while majority of malignant and intermediate tumours had positive p16 (7/7; 100%) and CDK4 (6/7; 85.7%) expression. These differences were found to be significant statistically (p16; $\chi^2=8.750$; $p=0.003$; CDK4; $\chi^2=11.429$; $p=0.001$).

Discussion

In present time apart from clinical and histomorphological picture there are many techniques to differentiate soft tissue tumors specially sarcomas. These techniques are immunohistochemistry, cytogenetics and molecular genetics. Immunohistochemistry is used to identify the differentiation of tumor cells in a particular section. Immunohistochemistry also plays a major role in soft tissue tumor classification, diagnosis, treatment and prognosis.

Genetic alterations involving the 12q13-15 chromosomal region are common in musculoskeletal sarcomas, and many bone and soft-tissue malignant tumors showed amplification of various genes located in this region¹⁰.

p16 is a tumor suppressor gene and it is an important cell cycle regulator. It inhibits cell cycle

at G1-S checkpoint by binding to cyclin-dependent kinases 4/6 and prevent inactivation of the Rb protein. p16 may be mutated or deleted in many cancers^[22,33-36].

Conclusion

Genetic alterations involving the 12q13-15 chromosomal region are common in musculoskeletal sarcomas, and many bone and soft-tissue malignant tumors showed amplification of various genes located in this region.

Ethical clearance: Taken from ethical committee of institution

Source of funding: Self

Conflict of Interest: Nil

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. *CA Cancer J Clin.* 2015;65:5-29.
2. Coindre J, Terrier P, Guillou L, Le Doussal V, Collin F, Ranchère D, et al. Predictive value of grade for metastases development in the main histological types of adult soft tissue sarcomas: A study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. *Cancer.* 2001;91:1914-26.
3. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA (April 1994). "Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers". *Nature.* 368(6473): 753-6
4. Rayess H, Wang MB, Srivatsan ES (April 2012). "Cellular senescence and tumor suppressor gene p16". *International Journal of Cancer.* 130 (8): 1715-25.
5. Aleixo PB, Hartmann AA, Menezes IC, Meurer RT, Oliveira AM. Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours. *Journal of clinical pathology.* 2009 Dec 1;62(12):1127-35.
6. Thway K, Flora R, Shah C, Olmos D, Fisher C. Diagnostic utility of p16, CDK4, and MDM2 as an immunohistochemical panel in distinguishing well-differentiated and dedifferentiated liposarcomas from other adipocytic tumors. *The American journal of surgical pathology.* 2012 Mar 1;36(3):462-9.
7. Dickson MA, Tap WD, Keohan ML, D'Angelo SP, Gounder MM, Antonescu CR, Landa J, Qin LX, Rathbone DD, Condy MM, Ustoyev Y. Phase II trial

-
- of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. *Journal of clinical oncology*. 2013 Jun 1;31(16):2024.
8. Khatib ZA, Matsushime H, Valentine M, Shapiro DN, Sherr CJ, Look AT. Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. *Cancer research*. 1993 Nov 15;53(22):5535-41.
 9. Binh MB, Sastre-Garau X, Guillou L, de Pinieux G, Terrier P, Lagacé R, Aurias A, Hostein I, Coindre JM. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. *The American journal of surgical pathology*. 2005 Oct 1;29(10):1340-7.